Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

3B Blackbio DX share price today

3BBLACKBIODiagnosticsConsolidatedPrices to 20 Nov 2026Results to Sep 2026

Price, 200-day average and NIFTY 500

The price is 3.7% below its 200-day average and 155 points ahead of the NIFTY 500 over 5 years

20 Nov 2026₹1,305.10Over 5 years: 3B Blackbio DX +211.6%, NIFTY 500 +56.2%
₹500₹2,000Nov 22Nov 24Nov 26

Price growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+1.8%3Y+21.7%/yr5Y+25.5%/yr10Y+52.7%/yr

EPS and P/E

EPS ₹68.30, up 19% in a year; P/E 19.1

20 Nov 2026₹68.30 EPS
Dec 21
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹75

EPS growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+19.4%3Y+22.8%/yr5Y+4.2%/yr10Y+48.6%/yr

Revenue and margins

Revenue up on a year for 6 quarters in a row; operating margin 43.8%

Sep 2026 quarter₹48 crore+41.2% on ₹34 crore a year earlier · NPM 37.5%
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹60

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+61.2%3Y+35.7%/yr5Y−9.0%/yr to Mar10Y+23.6%/yr to Mar
OPM average3Y43.6%5Y45.3% to Mar
NPM average3Y42.5%5Y43.5% to Mar

Return on capital

ROCE was 24.3% for the four quarters to Sep 2026, down from 27.0% in the year to Mar 2022

Four quarters to Sep 202624.3% ROCE
15%25%Sep 22Sep 24Sep 26

ROCE average

1Y3Y5Y10Y1Y24.3%3Y24.2% to Mar5Y23.9% to Mar10Y37.8% to Mar

Profit and cash

Cash from operations was 90% of profit over five years, 87% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹52 crore operating cashProfit ₹60 crore · Free cash ₹26 crore
FY22
FY23
FY24
FY25
FY26
0₹80

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+20.4%3Y+27.6%/yr5Y−12.0%/yr to Mar10YNot meaningful

Reinvestment

Capex was ₹26 crore in the year to Mar 2026, 5.1 times depreciation

FY26₹26 crore capexWork in progress ₹0 crore
FY22
FY23
FY24
FY25
FY26
0₹30

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+2,734.4% to Mar3Y+132.9%/yr to Mar5Y+72.3%/yr to Mar10Y+55.9%/yr to Mar

BorrowingsInsufficient history, from Dec 2022Insufficient history, from Dec 2022

Debt ÷ equity 0.01 at 30 Sep 2026

Sep 2026 balance sheet0.01 debt ÷ equityNet cash ₹98 crore
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0600x

Safety

Now3Y ago
Debt ÷ equity0.013Y ago0.01
Int. covern/a3Y agoAlmost none

Operating health

Working capital rose from 65 to 143 days in 5 years

Year to Mar 2026143 days working capital
100200Mar 22Mar 24Mar 26
Working cap.1431Y−263Y−985Y+78
Debtor1291Y−93Y−715Y+73
Inventory1871Y+633Y+235Yn/a

OwnershipInsufficient history, from Mar 2023Insufficient history, from Mar 2023

FIIs own 2.46%, down 0.18 points in a year. Promoters hold 40.95%

Share of the company held, %, by quarter end

Sep 2026 quarter2.46% FIIs
10%40%Sep 23Sep 24Sep 25Sep 26

Change in holding, in points

FIIs1Y−0.183Y−0.70
Promoters1Y−0.333Y+2.52

3B Blackbio DX Ltd · 3BBLACKBIO · Diagnostics · price as of the 20 November 2026 close, updated every trading day · results updated weekly · research updated 1 June 2026

3B Blackbio DX share price today: ₹1,305.10 at the close on 20 November 2026, up 1.8% in a year. 3B Blackbio DX (3BBLACKBIO) is worth ₹1,119 crore, trades at a P/E of 19.1 and has closed between ₹1,121.05 and ₹1,695.75 over the past 52 weeks. Latest change: indian funds and insurers (DIIs) raised their stake for 6 quarters in a row.

Growing steadilyBusiness trend from fewer quarters than usual
₹1,305.10Price +1.8% in a year
19.1×P/E higher than 56% of the last 11 years
₹48.0 CrRevenue (Sep 2026) +41.2% on a year ago
₹18.0 CrProfit (Sep 2026) +20.0% on a year ago
43.8%Operating margin −0.3 points on a year ago
24.3%ROCE four quarters to Sep 2026
87%Profit that came in as cash last 3 years

3B Blackbio DX Ltd's earnings have grown faster than its share price. Earnings per share grew +19.4% in a year while the price moved +1.8%.

Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business.

The price is in an uptrend that has just slipped below its 200-day average, and the P/E is higher than 56% of its own last 11 years. Over the last four quarters, results have been improving, with profit +20.0% on a year earlier, and 87% of the last 3 years' profit came in as cash. What will decide it: the next one or two quarters of results.

Left out of this page: Its two data sources disagree by up to 41% on reported income across 15 comparable periods, so nothing from the second source is shown here. That is why the quarterly PEG curve, the yearly return-on-capital-used (ROIC) line, the total-debt and debt-to-equity series and the F-score and the return-on-capital-used (ROIC) reading are missing. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. The quarterly history also starts where the main source starts: 5 earlier quarters from the second source are not added in front of it. Adding to a profit history needs a source that has been checked.

What is the 3B Blackbio DX share price today?

3B Blackbio DX Ltd's share price was ₹1,305.10 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 3.7% below its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today 3B Blackbio DX Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹1,121 and ₹1,696, and at that close it sat 32% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running.

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 307 of 554 weeks

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
11 Mar 2016no NIFTY 500 reading
18 Mar 2016no NIFTY 500 reading
23 Mar 2016no NIFTY 500 reading
1 Apr 2016no NIFTY 500 reading
8 Apr 2016no NIFTY 500 reading
13 Apr 2016no NIFTY 500 reading
22 Apr 2016no NIFTY 500 reading
29 Apr 2016no NIFTY 500 reading
6 May 2016no NIFTY 500 reading
13 May 2016no NIFTY 500 reading
20 May 2016no NIFTY 500 reading
27 May 2016no NIFTY 500 reading
3 Jun 2016no NIFTY 500 reading
10 Jun 2016−5.3%
15 Jun 2016+10.1%
24 Jun 2016−7.9%
1 Jul 2016+15.1%
8 Jul 2016+25.2%
14 Jul 2016+18.4%
22 Jul 2016+7.7%
29 Jul 2016+9.1%
5 Aug 2016−7.7%
12 Aug 2016−24.9%
19 Aug 2016−22.1%
26 Aug 2016−8.5%
2 Sep 2016+17.3%
9 Sep 2016+26.1%
16 Sep 2016+35.8%
23 Sep 2016+47.3%
30 Sep 2016+41.3%
7 Oct 2016+19.0%
14 Oct 2016+54.4%
21 Oct 2016+59.3%
28 Oct 2016+46.2%
4 Nov 2016+54.6%
11 Nov 2016+87.3%
18 Nov 2016+70.3%
25 Nov 2016+67.6%
2 Dec 2016+93.8%
9 Dec 2016+94.5%
16 Dec 2016+69.5%
23 Dec 2016+83.3%
30 Dec 2016+68.9%
6 Jan 2017+75.9%
13 Jan 2017+106.1%
20 Jan 2017+76.7%
27 Jan 2017+85.1%
3 Feb 2017+98.1%
10 Feb 2017+39.2%
17 Feb 2017+43.1%
23 Feb 2017+64.5%
3 Mar 2017+12.8%
10 Mar 2017+11.9%
17 Mar 2017+14.2%
24 Mar 2017+39.3%
31 Mar 2017+26.3%
7 Apr 2017+29.7%
13 Apr 2017−8.3%
21 Apr 2017+44.1%
28 Apr 2017+51.5%
5 May 2017+26.4%
12 May 2017+47.8%
19 May 2017+60.2%
26 May 2017+28.0%
2 Jun 2017+37.8%
9 Jun 2017+31.9%
16 Jun 2017+47.0%
23 Jun 2017+34.1%
30 Jun 2017+51.0%
7 Jul 2017+22.6%
14 Jul 2017+3.5%
21 Jul 2017−18.7%
28 Jul 2017−24.5%
4 Aug 2017+3.1%
11 Aug 2017+13.2%
18 Aug 2017−6.7%
24 Aug 2017+9.2%
1 Sep 2017+43.4%
8 Sep 2017+52.0%
15 Sep 2017+64.2%
22 Sep 2017+41.8%
29 Sep 2017+42.7%
6 Oct 2017+86.5%
13 Oct 2017+103.9%
19 Oct 2017+83.9%
27 Oct 2017+93.8%
3 Nov 2017+50.2%
10 Nov 2017+37.9%
17 Nov 2017+87.8%
24 Nov 2017+122.3%
1 Dec 2017+100.9%
8 Dec 2017+46.5%
15 Dec 2017+30.4%
22 Dec 2017+22.6%
29 Dec 2017+30.4%
5 Jan 2018+33.2%
12 Jan 2018+76.5%
19 Jan 2018+65.3%
25 Jan 2018+67.4%
2 Feb 2018+74.7%
9 Feb 2018+83.6%
16 Feb 2018+49.9%
23 Feb 2018+26.6%
1 Mar 2018+24.2%
9 Mar 2018+41.0%
16 Mar 2018+35.9%
23 Mar 2018+35.0%
28 Mar 2018+27.6%
6 Apr 2018+17.9%
13 Apr 2018−13.7%
20 Apr 2018+11.9%
27 Apr 2018+20.6%
4 May 2018+17.6%
11 May 2018+11.8%
18 May 2018+16.6%
25 May 2018+6.0%
1 Jun 2018−0.5%
8 Jun 2018+0.8%
15 Jun 2018+0.8%
22 Jun 2018−2.3%
29 Jun 2018+0.0%
6 Jul 2018−4.6%
13 Jul 2018+6.2%
20 Jul 2018−6.8%
27 Jul 2018−20.1%
3 Aug 2018−25.0%
10 Aug 2018−36.3%
17 Aug 2018−39.2%
24 Aug 2018−47.6%
31 Aug 2018−42.8%
7 Sep 2018−42.1%
14 Sep 2018−33.1%
21 Sep 2018−36.3%
28 Sep 2018−43.4%
5 Oct 2018−32.2%
12 Oct 2018−28.5%
19 Oct 2018−33.8%
26 Oct 2018−39.0%
2 Nov 2018−36.6%
9 Nov 2018−29.2%
16 Nov 2018−16.1%
22 Nov 2018+5.8%
30 Nov 2018−5.9%
7 Dec 2018+1.0%
14 Dec 2018−7.0%
21 Dec 2018+18.4%
28 Dec 2018+20.3%
4 Jan 2019−1.7%
11 Jan 2019+1.3%
18 Jan 2019+6.1%
25 Jan 2019+16.0%
1 Feb 2019+2.5%
8 Feb 2019−0.8%
15 Feb 2019−18.0%
22 Feb 2019−21.0%
1 Mar 2019−12.3%
8 Mar 2019−16.8%
15 Mar 2019−4.0%
22 Mar 2019−23.9%
29 Mar 2019−24.4%
5 Apr 2019−4.8%
12 Apr 2019−19.0%
18 Apr 2019−14.8%
26 Apr 2019−3.2%
3 May 2019+8.1%
10 May 2019+19.3%
17 May 2019+13.1%
24 May 2019+20.8%
31 May 2019+14.2%
7 Jun 2019+21.2%
14 Jun 2019+4.9%
21 Jun 2019+17.4%
28 Jun 2019+23.3%
5 Jul 2019+4.4%
12 Jul 2019+7.4%
19 Jul 2019+5.8%
26 Jul 2019+0.8%
2 Aug 2019+10.2%
9 Aug 2019+7.3%
16 Aug 2019+12.0%
23 Aug 2019+10.9%
30 Aug 2019+10.1%
6 Sep 2019+2.0%
13 Sep 2019+7.1%
20 Sep 2019+3.5%
27 Sep 2019+0.7%
4 Oct 2019−2.9%
11 Oct 2019−1.6%
18 Oct 2019+1.3%
27 Oct 2019+0.7%
1 Nov 2019−10.6%
8 Nov 2019−8.3%
15 Nov 2019−5.0%
22 Nov 2019−15.5%
29 Nov 2019−15.0%
6 Dec 2019−8.5%
13 Dec 2019−21.0%
20 Dec 2019−13.4%
27 Dec 2019−10.5%
3 Jan 2020−1.9%
10 Jan 2020−2.6%
17 Jan 2020−2.4%
24 Jan 2020−1.2%
1 Feb 2020+13.0%
7 Feb 2020+11.5%
14 Feb 2020−2.7%
20 Feb 2020+0.8%
28 Feb 2020−1.8%
6 Mar 2020−3.6%
13 Mar 2020−2.2%
20 Mar 2020−0.3%
27 Mar 2020+6.6%
3 Apr 2020+26.0%
9 Apr 2020+61.3%
17 Apr 2020+70.6%
24 Apr 2020+68.5%
30 Apr 2020+50.5%
8 May 2020+90.6%
15 May 2020+119.8%
22 May 2020+113.3%
29 May 2020+115.4%
5 Jun 2020+60.3%
12 Jun 2020+135.3%
19 Jun 2020+141.8%
26 Jun 2020+130.4%
3 Jul 2020+101.8%
10 Jul 2020+66.8%
17 Jul 2020+98.1%
24 Jul 2020+137.3%
31 Jul 2020+204.6%
7 Aug 2020+177.9%
14 Aug 2020+158.8%
21 Aug 2020+140.9%
28 Aug 2020+127.9%
4 Sep 2020+186.0%
11 Sep 2020+83.2%
18 Sep 2020+65.7%
25 Sep 2020+60.6%
1 Oct 2020+46.6%
9 Oct 2020+46.8%
16 Oct 2020+37.5%
23 Oct 2020+10.2%
30 Oct 2020−12.4%
6 Nov 2020−27.2%
14 Nov 2020−30.0%
20 Nov 2020−26.3%
27 Nov 2020−20.0%
4 Dec 2020−28.8%
11 Dec 2020−18.9%
18 Dec 2020−16.7%
24 Dec 2020−7.9%
1 Jan 2021−7.0%
8 Jan 2021−27.9%
15 Jan 2021−41.0%
22 Jan 2021−38.4%
29 Jan 2021−34.7%
5 Feb 2021−42.1%
12 Feb 2021−40.1%
19 Feb 2021−33.7%
26 Feb 2021−35.3%
5 Mar 2021−18.2%
12 Mar 2021−21.3%
19 Mar 2021−15.4%
26 Mar 2021−18.0%
1 Apr 2021−25.0%
9 Apr 2021−4.1%
16 Apr 2021−10.5%
23 Apr 2021+14.4%
30 Apr 2021+20.2%
7 May 2021+27.5%
14 May 2021+31.9%
21 May 2021+26.4%
28 May 2021+36.3%
4 Jun 2021+36.6%
11 Jun 2021+41.2%
18 Jun 2021+42.2%
25 Jun 2021+70.1%
2 Jul 2021+100.7%
9 Jul 2021+74.3%
16 Jul 2021+78.5%
23 Jul 2021+74.3%
30 Jul 2021+46.5%
6 Aug 2021+36.4%
13 Aug 2021+18.8%
20 Aug 2021+19.2%
27 Aug 2021+23.0%
3 Sep 2021+10.3%
9 Sep 2021+9.0%
17 Sep 2021+8.1%
24 Sep 2021−23.1%
1 Oct 2021−35.7%
8 Oct 2021−32.1%
14 Oct 2021−33.1%
22 Oct 2021−50.1%
29 Oct 2021−41.2%
4 Nov 2021−37.1%
12 Nov 2021−29.2%
18 Nov 2021−29.1%
26 Nov 2021−20.0%
3 Dec 2021−14.2%
10 Dec 2021−14.8%
17 Dec 2021−15.3%
24 Dec 2021−3.5%
31 Dec 2021−3.4%
7 Jan 2022+0.7%
14 Jan 2022−7.6%
21 Jan 2022+1.2%
28 Jan 2022+0.8%
4 Feb 2022+1.6%
11 Feb 2022−9.5%
18 Feb 2022−2.5%
25 Feb 2022−13.2%
4 Mar 2022−8.5%
11 Mar 2022−2.5%
17 Mar 2022−9.5%
25 Mar 2022−14.7%
1 Apr 2022−22.3%
8 Apr 2022−25.7%
13 Apr 2022−15.7%
22 Apr 2022−11.6%
29 Apr 2022−17.2%
6 May 2022−14.5%
13 May 2022−1.9%
20 May 2022−4.3%
27 May 2022−4.9%
3 Jun 2022−10.1%
10 Jun 2022−11.6%
17 Jun 2022−3.1%
24 Jun 2022−2.9%
1 Jul 2022+0.3%
8 Jul 2022−8.0%
15 Jul 2022−7.8%
22 Jul 2022−15.8%
29 Jul 2022−11.6%
5 Aug 2022−17.2%
12 Aug 2022−3.6%
19 Aug 2022−6.9%
26 Aug 2022+2.1%
2 Sep 2022+1.0%
9 Sep 2022−7.3%
16 Sep 2022−12.3%
23 Sep 2022−5.8%
30 Sep 2022−4.1%
7 Oct 2022+1.1%
14 Oct 2022−0.5%
21 Oct 2022+1.8%
28 Oct 2022+1.7%
4 Nov 2022+2.0%
11 Nov 2022−15.6%
18 Nov 2022+13.8%
25 Nov 2022+2.0%
2 Dec 2022+9.3%
9 Dec 2022+21.7%
16 Dec 2022+21.3%
23 Dec 2022+32.9%
30 Dec 2022+36.2%
6 Jan 2023+29.8%
13 Jan 2023+30.2%
20 Jan 2023+28.1%
27 Jan 2023+23.0%
3 Feb 2023+22.1%
10 Feb 2023+25.6%
17 Feb 2023+1.1%
24 Feb 2023+10.5%
3 Mar 2023−1.2%
10 Mar 2023−2.9%
17 Mar 2023+3.3%
24 Mar 2023−8.7%
31 Mar 2023−5.0%
6 Apr 2023+0.4%
13 Apr 2023+0.5%
21 Apr 2023+4.3%
28 Apr 2023+5.0%
5 May 2023+7.3%
12 May 2023+6.3%
19 May 2023+2.5%
26 May 2023−3.9%
2 Jun 2023−3.9%
9 Jun 2023+0.6%
16 Jun 2023−8.4%
23 Jun 2023−9.8%
30 Jun 2023−11.3%
7 Jul 2023−16.1%
14 Jul 2023−16.4%
21 Jul 2023−15.2%
28 Jul 2023−3.0%
4 Aug 2023+2.6%
11 Aug 2023+8.8%
18 Aug 2023+28.3%
25 Aug 2023+30.3%
1 Sep 2023+39.0%
8 Sep 2023+75.6%
15 Sep 2023+73.5%
22 Sep 2023+73.8%
29 Sep 2023+81.0%
6 Oct 2023+77.7%
13 Oct 2023+67.3%
20 Oct 2023+73.8%
27 Oct 2023+67.3%
3 Nov 2023+53.9%
12 Nov 2023+36.2%
17 Nov 2023+17.1%
24 Nov 2023+15.3%
1 Dec 2023+9.9%
8 Dec 2023−24.9%
15 Dec 2023−13.7%
22 Dec 2023−1.2%
29 Dec 2023−11.9%
5 Jan 2024+3.6%
12 Jan 2024−4.5%
20 Jan 2024−7.0%
25 Jan 2024−11.8%
2 Feb 2024−3.9%
9 Feb 2024−2.8%
16 Feb 2024−1.1%
23 Feb 2024+9.4%
2 Mar 2024+9.2%
7 Mar 2024+10.3%
15 Mar 2024−1.5%
22 Mar 2024−14.7%
28 Mar 2024−6.8%
5 Apr 2024−22.7%
12 Apr 2024−5.8%
19 Apr 2024−9.9%
26 Apr 2024−10.2%
3 May 2024−19.2%
10 May 2024−14.6%
18 May 2024−7.2%
24 May 2024−14.9%
31 May 2024+0.6%
7 Jun 2024+11.6%
14 Jun 2024+34.4%
21 Jun 2024+42.9%
28 Jun 2024+34.3%
5 Jul 2024+54.0%
12 Jul 2024+30.4%
19 Jul 2024+23.6%
26 Jul 2024+21.0%
2 Aug 2024+58.0%
9 Aug 2024+55.0%
16 Aug 2024+63.0%
23 Aug 2024+73.1%
30 Aug 2024+43.2%
6 Sep 2024+43.3%
13 Sep 2024+22.1%
20 Sep 2024+8.1%
27 Sep 2024+9.1%
4 Oct 2024+5.1%
11 Oct 2024+23.8%
18 Oct 2024+28.8%
25 Oct 2024+32.9%
1 Nov 2024+18.8%
8 Nov 2024+18.8%
14 Nov 2024+27.8%
22 Nov 2024+18.0%
29 Nov 2024+24.8%
6 Dec 2024+35.6%
13 Dec 2024+48.3%
20 Dec 2024+53.9%
27 Dec 2024+60.4%
3 Jan 2025+59.2%
10 Jan 2025+50.2%
17 Jan 2025+54.6%
24 Jan 2025+40.6%
1 Feb 2025+32.1%
7 Feb 2025+48.9%
14 Feb 2025+18.1%
21 Feb 2025+20.1%
28 Feb 2025+14.8%
7 Mar 2025+7.6%
13 Mar 2025−6.2%
21 Mar 2025−5.4%
28 Mar 2025−14.5%
4 Apr 2025−7.2%
11 Apr 2025−7.3%
17 Apr 2025−10.5%
25 Apr 2025−9.0%
2 May 2025−11.2%
9 May 2025−17.0%
16 May 2025−21.0%
23 May 2025−21.0%
30 May 2025−17.0%
6 Jun 2025−26.4%
13 Jun 2025−19.7%
20 Jun 2025−24.7%
27 Jun 2025−22.4%
4 Jul 2025−22.3%
11 Jul 2025−26.1%
18 Jul 2025−21.0%
25 Jul 2025−22.6%
1 Aug 2025−11.0%
8 Aug 2025−13.0%
14 Aug 2025−2.1%
22 Aug 2025−15.3%
29 Aug 2025−11.9%
5 Sep 2025−7.4%
12 Sep 2025−11.0%
19 Sep 2025−8.2%
26 Sep 2025−0.6%
3 Oct 2025−7.1%
10 Oct 2025−7.5%
17 Oct 2025−11.2%
24 Oct 2025−6.5%
31 Oct 2025−15.2%
7 Nov 2025−16.8%
14 Nov 2025−21.0%
21 Nov 2025−14.3%
28 Nov 2025−16.9%
5 Dec 2025−18.9%
12 Dec 2025−5.6%
19 Dec 2025−3.1%
26 Dec 2025−2.5%
2 Jan 2026−5.6%
9 Jan 2026+4.3%
16 Jan 2026+22.8%
23 Jan 2026+22.2%
1 Feb 2026+19.9%
6 Feb 2026+22.8%
13 Feb 2026+16.7%
20 Feb 2026+27.5%
27 Feb 2026+8.3%
6 Mar 2026+5.1%
13 Mar 2026−4.1%
20 Mar 2026+6.1%
27 Mar 2026−4.6%
2 Apr 2026+0.3%
10 Apr 2026−11.2%
17 Apr 2026−20.1%
24 Apr 2026−18.6%
30 Apr 2026−23.6%
8 May 2026−19.1%
15 May 2026−10.5%
22 May 2026−22.4%
29 May 2026−5.7%
4 Jun 2026−9.7%
5 Jun 2026−10.6%
9 Jun 2026−12.9%
10 Jun 2026+0.0%
12 Jun 2026−6.2%
17 Jun 2026−5.1%
19 Jun 2026−9.7%
24 Jun 2026−13.6%
25 Jun 2026−5.6%
1 Jul 2026−8.3%
3 Jul 2026−18.0%
10 Jul 2026−6.9%
17 Jul 2026−2.5%
24 Jul 2026+11.2%
31 Jul 2026+6.9%
7 Aug 2026−4.7%
14 Aug 2026−10.9%
21 Aug 2026−8.2%
28 Aug 2026+17.8%
4 Sep 2026+21.7%
11 Sep 2026+22.4%
18 Sep 2026+14.7%
25 Sep 2026+24.6%
28 Sep 2026+35.2%
1 Oct 2026+49.2%
9 Oct 2026+33.2%
16 Oct 2026+15.9%
23 Oct 2026+15.6%
30 Oct 2026+14.8%
6 Nov 2026+10.0%
8 Nov 2026+6.8%
13 Nov 2026−7.6%
20 Nov 2026−13.0%
Each bar is one week, from 2016 to now (554 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 11 years the share price moved +13,933% while the NIFTY 500 moved +279%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 8 November 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at 3B Blackbio DX this quarter?

Two changes stood out: indian funds and insurers (DIIs) raised their stake for 6 quarters in a row and revenue up on a year earlier for 6 quarters in a row.

  1. Indian funds and insurers (DIIs) raised their stake for 6 quarters in a row

    From 1.6% to 2.3% of the company by the September 2026 quarter.

  2. Revenue up on a year earlier for 6 quarters in a row

    In the September 2026 quarter revenue was ₹48 crore, +41.2% on a year earlier.

What are 3B Blackbio DX's latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), 3B Blackbio DX reported revenue of ₹48.0 crore, up 41.2% from ₹34.0 crore a year earlier, and a profit of ₹18.0 crore, up 20.0% from ₹15.0 crore.

3B Blackbio DX results: July to September 2026 against a year earlier

3B Blackbio DX results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹48.0 crore₹34.0 crore+41.2%
Profit₹18.0 crore₹15.0 crore+20.0%
Earnings per share₹20.74₹17.14+21.0%
Operating margin43.8%44.1%−0.3 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 1 June 2026, about January to March 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the 3B Blackbio DX share price history?

3B Blackbio DX closed at ₹1,305.10 on 20 November 2026, up 1.8% from ₹1,281.40 a year earlier (21 November 2025) and up 211.6% over five years. Its highest weekly close since March 2016 was ₹2,097.45 on 13 December 2024.

3B Blackbio DX share price: then and now

3B Blackbio DX share price: then and now
WhenCloseChange to 20 Nov 2026
1 week ago · 13 Nov 2026₹1,341.50−2.7%
1 month ago · 19 Oct 2026₹1,331.20−2.0%
6 months ago · 22 May 2026₹1,199.20+8.8%
1 year ago · 21 Nov 2025₹1,281.40+1.8%
3 years ago · 17 Nov 2023₹723.50+80.4%
5 years ago · 18 Nov 2021₹418.80+211.6%
10 years ago · 18 Nov 2016₹18.90+6,805.3%
Earliest weekly close in our records · 11 Mar 2016₹9.30+13,933.3%
Highest weekly close since March 2016 · 13 Dec 2024₹2,097.45−37.8%
Lowest weekly close since March 2016 · 1 Apr 2016₹8.25+15,719.4%
52-week high (weekly close) · 16 Jan 2026₹1,695.75−23.0%
52-week low (weekly close) · 5 Jun 2026₹1,121.05+16.4%

Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

567 weekly closes from 11 March 2016 to 20 November 2026.

What is the latest news on 3B Blackbio DX?

20 Nov 2026: 3B Blackbio DX closed at ₹1,305.10, down 2.7% on the week and down 2.0% on the month. Results for July to September 2026: Revenue up 41.2% and profit up 20.0% on a year earlier.

Earlier

  • 22 Sep 2026: ex-date for a dividend of ₹5 a share.
  • 1 Jun 2026: 3B Blackbio DX held its results call for January to March 2026.

What dividend does 3B Blackbio DX pay?

3B Blackbio DX paid ₹5 a share in regular dividends in the 12 months to 20 November 2026 (1 payment), a yield of 0.38% at the ₹1,305.10 close on 20 November 2026. The last was a dividend of ₹5 a share, ex-date 22 September 2026.

3B Blackbio DX dividends since 1 April 2021

3B Blackbio DX dividends since 1 April 2021
Ex-dateDividend per shareType
22 Sep 2026Dividend₹5Dividend

Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

0 of 5Of the last 5 financial years, years with an exchange dividend record

Yes. 3B Blackbio DX Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years.

From the exchange corporate-actions record, read 20 November 2026.

What to watch in 3B Blackbio DX's next results?

When 3B Blackbio DX reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier.

  • Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was +41.2% on a year earlier, and the last four quarters averaged +62.6%.
  • Whether the operating margin stays near 43.8%. It is 0.3 percentage points lower than four quarters earlier.
  • Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +20.0% on a year earlier.

Which stock lists is 3B Blackbio DX on?

3B Blackbio DX is on one of our India lists: Healthcare & hospital stocks.

Is 3B Blackbio DX profitable?

3B Blackbio DX Ltd earned ₹18.0 Cr of net profit in the Sep 2026 quarter, +20.0% on the same quarter a year earlier. Full-year FY26 profit was ₹60.0 Cr. The Sep 2026 quarter's profit is 37.5% of that quarter's revenue. The same quarter a year earlier earned ₹15.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹60.0 Cr (+25.0% on the year before).

Why profit moved: revenue changed +41.2% on a year earlier and the margin moved −0.3 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +20.9% and revenue +62.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

How much revenue does 3B Blackbio DX make, and is it growing?

3B Blackbio DX Ltd reported ₹48.0 Cr of revenue in the Sep 2026 quarter, +41.2% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 23.6% a year on average. The last full year, FY26, came in at ₹142 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹166 Cr.

FY26 revenue was ₹142 Cr, +47.9% on the year before.

Recent pace: the last four quarters grew +62.6% on average, against 23.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +61.2%, against +36.6% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +20.4%, against +15.8% a year (accelerating).

How much of every ₹100 of sales does 3B Blackbio DX keep?

3B Blackbio DX Ltd's operating margin was 43.8% in the Sep 2026 quarter, 0.3 percentage points lower than the same quarter a year ago. Across 13 years it has been between 4.5% and 66.1%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed +4.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Is 3B Blackbio DX's profit turning into cash?

Over the last 3 years, 87% of 3B Blackbio DX Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹52.0 Cr of operating cash against ₹60.0 Cr of profit. After ₹26.0 Cr of spending on assets, ₹26.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 87% of profit came in as cash: the cash cycle got 189 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 4.0× depreciation over three years. The next section checks what that spending is building.

Where does 3B Blackbio DX's cash go?

3B Blackbio DX Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 245 days in FY26, up from 56 days in FY21. It spent ₹28.0 Cr on assets over the last 3 years. Customers take 129 days to pay, and stock sits for 187 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹142 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹95.0 Cr is tied up in the business at any time.

FY26: customers took 129 days to pay and stock sat for 187 days, about 6.2 months of sales sitting as stock, for a full cycle of 245 days, longer than FY21's 56.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 187 days. Customers pay about 129 days after that. Suppliers are paid at 70 days. Together that makes the 245-day cycle.

Spending on assets: ₹28.0 Cr over the last 3 years, against ₹7.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is 3B Blackbio DX's P/E ratio, and how does it compare with its own history?

3B Blackbio DX Ltd's P/E is 19.1×, in the middle of its own history: higher than 56% of past readings. Its usual P/E (the middle reading) is 17.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

19.1×P/E · higher than 56% of its last 11 years

Why the multiple is where it is: over the past year earnings per share moved +19.4% while the price moved +1.8%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved +25.5% a year; about +4.2% a year came from earnings growth and about +21.3 percentage points from the multiple (the market paying more); over 10 years the price moved +52.7% a year; about +48.6% a year came from earnings growth and about +4.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 41% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Is the 3B Blackbio DX business getting better or worse?

3B Blackbio DX Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 24.3% (four quarters to Sep 2026). This is based on 9 quarters of 4 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

RisingRevenue growth · latest (Sep 2026) +61.2%, range +15.7% to +61.2%
Steady highProfit growth · latest (Sep 2026) +20.4%, range +11.4% to +63.3%
Steady highEPS growth · latest (Sep 2026) +19.4%, range +13.2% to +47.1%
Steady highROCE · latest (four quarters to Sep 2026) 24.3%, range 19.0% to 26.0%

Why it matters: steady growth with healthy returns is how a business compounds over time.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+47.9%+31.8%−9.0%+23.6%
Profit+25.0%+32.1%−12.0%—
EPS+22.9%+25.5%−14.8%+63.2%
Share price+1.8%+21.7%+25.5%+52.7%
+41.2%Revenue growth (Sep 2026) · latest quarter against a year ago
+20.0%Profit growth (Sep 2026) · latest quarter against a year ago
23.6%Revenue, 10 years · yearly growth over the long run

How much does 3B Blackbio DX earn on its capital?

3B Blackbio DX Ltd earned a ROCE of 25% in FY26. That is up from a low of 7% in FY14. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 42.3% net margin and 0.38× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 42.3% net margin × 0.38× asset turnover × 1.16× leverage (assets divided by equity) ≈ 18.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 41% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Does 3B Blackbio DX have too much debt?

3B Blackbio DX Ltd had ₹3.0 Cr of borrowings against ₹325 Cr of equity in FY26, so its debt is 0.01× its equity. Over 5 years borrowings went from ₹2.0 Cr to ₹3.0 Cr. Over the last 3 of those years it spent ₹28.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 41% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What is the 3B Blackbio DX shareholding pattern?

No group of 3B Blackbio DX Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.4 points over the same period, to 2.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: −0.8 points over 8 quarters, to 2.5%; Domestic institutions: +0.4 points over 8 quarters, to 2.3%; Promoters: −0.3 points over 8 quarters, to 41.0%.

How far is 3B Blackbio DX from balance-sheet trouble?

For 3B Blackbio DX Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does 3B Blackbio DX rank in its industry?

55.8 out of 100, rank 5 of 9 in Diagnostics, with 82% of the evidence available.

3B Blackbio DX Ltd scores 55.8 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 21.2 + 17.9 + 8.9 + 7.8 = 55.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is 3B Blackbio DX compared with?

3B Blackbio DX ranks 5 of 9 Diagnostics companies on the 4-Factor Sector Score, with 55.8 out of 100.

  1. 1Suraksha Diagnostic LtdSURAKSHA · leader · Most evidence points up · 93% evidence71.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.7/35 · Revenue 24.9% · Profit 32.3% · Operating margin change 4 points · 100% evidenceCapital efficiency 11.4/25 · ROCE 17.3% (year to Mar 2026) · Operating margin 35.4% · 100% evidenceValuation 12.9/20 · P/E 38.8× · PEG 1.4 · 65% evidenceRelative strength 18.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.6% · Strength vs NIFTY 500 (same reading) 14.5% · 1 year 4% · 100% evidence · 12 of 12 weeks aheadExact sum: 28.7 + 11.4 + 12.9 + 18.6 = 71.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Metropolis Healthcare LtdMETROPOLIS · turning · Most evidence points up · 100% evidence67.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.6/35 · Revenue 19.9% · Profit 42.4% · Operating margin change 2 points · 100% evidenceCapital efficiency 13.8/25 · ROCE 17.8% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 11.0/20 · P/E 52.3× · PEG 2.03 · 100% evidenceRelative strength 13.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 3.1% · Strength vs NIFTY 500 (same reading) 5.7% · 1 year 15.8% · 100% evidence · 4 of 12 weeks aheadExact sum: 28.6 + 13.8 + 11 + 13.9 = 67.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3Dr Lal Pathlabs LtdLALPATHLAB · losing its lead · Evidence leans up · 100% evidence58.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 15.5/35 · Revenue 16.7% · Profit 8.7% · Operating margin change 1 points · 100% evidenceCapital efficiency 19.3/25 · ROCE 28% (year to Mar 2026) · Operating margin 32% · 100% evidenceValuation 5.3/20 · P/E 57.5× · PEG 2.81 · 100% evidenceRelative strength 18.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 16.1% · Strength vs NIFTY 500 (same reading) 18.6% · 1 year 27.7% · 100% evidence · 11 of 12 weeks aheadExact sum: 15.5 + 19.3 + 5.3 + 18.1 = 58.2 · What this means: Relative strength against the index is 18.6%, and revenue and profit growth are weak.
  4. 4Vijaya Diagnostic Centre LtdVIJAYA · losing its lead · Evidence leans up · 100% evidence57.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.1/35 · Revenue 24.3% · Profit 33.5% · Operating margin change 3 points · 100% evidenceCapital efficiency 17.5/25 · ROCE 20.5% (year to Mar 2026) · Operating margin 44.3% · 100% evidenceValuation 0.7/20 · P/E 79.5× · PEG 2.88 · 100% evidenceRelative strength 12.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 10.5% · Strength vs NIFTY 500 (same reading) 12.5% · 1 year 56.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 27.1 + 17.5 + 0.7 + 12.1 = 57.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  5. 53B Blackbio DX Ltd this page3BBLACKBIO · breaking out · Evidence leans up · 82% evidence55.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.2/35 · Revenue 61.2% · Profit 20.4% · Operating margin change 1 points · 95% evidenceCapital efficiency 17.9/25 · ROCE 25.5% (year to Mar 2026) · Operating margin 43.8% · 76% evidenceValuation 8.9/20 · P/E 19.1× · PEG — · 50% evidenceRelative strength 7.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -6.3% · Strength vs NIFTY 500 (same reading) -3.4% · 1 year 1.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 21.2 + 17.9 + 8.9 + 7.8 = 55.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Thyrocare Technologies LtdTHYROCARE · quiet · Evidence leans up · 100% evidence55.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.1/35 · Revenue 22% · Profit 12.6% · Operating margin change 0 points · 100% evidenceCapital efficiency 20.6/25 · ROCE 35.4% (year to Mar 2026) · Operating margin 32.8% · 100% evidenceValuation 7.6/20 · P/E 58.3× · PEG 2.42 · 100% evidenceRelative strength 5.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -1.1% · Strength vs NIFTY 500 (same reading) 1% · 1 year 3.3% · 100% evidence · 3 of 12 weeks aheadExact sum: 21.1 + 20.6 + 7.6 + 5.9 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7One Global Service Provider LtdONEGLOBAL · quiet · Evidence leans up · 75% evidence51.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 15.9/35 · Revenue 42.6% · Profit 41.6% · Operating margin change -2.6 points · 100% evidenceCapital efficiency 13.9/25 · ROCE 87% (year to Mar 2026) · Operating margin 16.7% · 100% evidenceValuation 13.9/20 · P/E 11.7× · PEG — · 50% evidenceRelative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -31.6% · 1 year -30.3% · 25% evidence · 0 of 7 weeks aheadExact sum: 15.9 + 13.9 + 13.9 + 7.5 = 51.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Krsnaa Diagnostics LtdKRSNAA · quiet · Evidence leans down · 75% evidence40.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 9.4/35 · Revenue 15.9% · Profit 16.5% · Operating margin change -3 points · 100% evidenceCapital efficiency 8.4/25 · ROCE 12.7% (year to Mar 2026) · Operating margin 26.2% · 100% evidenceValuation 14.6/20 · P/E 17.2× · PEG — · 50% evidenceRelative strength 7.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -15.3% · 1 year -36.4% · 25% evidence · 0 of 12 weeks aheadExact sum: 9.4 + 8.4 + 14.6 + 7.9 = 40.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.
  9. 9Vimta Labs LtdVIMTALABS · quiet · Evidence leans down · 90% evidence35.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 8.3/35 · Revenue 11.7% · Profit 2.5% · Operating margin change 0 points · 100% evidenceCapital efficiency 15.4/25 · ROCE 25.2% (year to Mar 2026) · Operating margin 33.9% · 100% evidenceValuation 9.2/20 · P/E 26× · PEG — · 50% evidenceRelative strength 2.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -11.7% · Strength vs NIFTY 500 (same reading) -9.5% · 1 year -23.5% · 100% evidence · 5 of 12 weeks aheadExact sum: 8.3 + 15.4 + 9.2 + 2.5 = 35.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Diagnostics, all 9 compared on one page.

Which companies are close to 3B Blackbio DX in size?

3B Blackbio DX is the 8th largest of 9 Diagnostics companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Metropolis Healthcare, Thyrocare Technologies, Vimta Labs, Krsnaa Diagnostics and Suraksha Diagnostic. Just below it: One Global Service Provider.

Diagnostics companies close in size

  1. Metropolis Healthcare Ltd ₹11,746 crore
  2. Thyrocare Technologies Ltd ₹8,421 crore
  3. Vimta Labs Ltd ₹2,090 crore
  4. Krsnaa Diagnostics Ltd ₹1,684 crore
  5. Suraksha Diagnostic Ltd ₹1,623 crore
  6. 3B Blackbio DX Ltd ₹1,120 crore
  7. One Global Service Provider Ltd ₹729 crore

All 9 Diagnostics companies, largest first

Companies close in size in other industries

  1. String Metaverse Ltd ₹1,120 crore · IT - Software
  2. N R Agarwal Industries Ltd ₹1,120 crore · Paper
  3. 3B Blackbio DX Ltd ₹1,120 crore
  4. Macfos Ltd ₹1,119 crore · E-Commerce - Platform - Utility
  5. IZMO Ltd ₹1,114 crore · IT - Software

What else do people ask about 3B Blackbio DX?

What were 3B Blackbio DX's latest quarterly results?

3B Blackbio DX Ltd reported revenue of ₹48.0 Cr and net profit of ₹18.0 Cr for the Sep 2026 quarter. Revenue rose 41.2% and profit rose 20.0% compared with a year earlier. Earnings per share were ₹20.74.

The operating margin was 43.8%, 0.3 percentage points lower than a year earlier (as of 20 November 2026).

What is 3B Blackbio DX's market cap?

3B Blackbio DX Ltd's market capitalisation is ₹1,119 Cr at a share price of ₹1,305.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026).

How is 3B Blackbio DX performing?

3B Blackbio DX Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 41.2% and profit rose 20.0% compared with a year earlier. This describes what the data did, not a rating (as of 20 November 2026).

Will 3B Blackbio DX's share price go up?

This page does not forecast 3B Blackbio DX Ltd's share price. What it shows instead: the share price is ₹1,305.10, and it has been rising for 7 weeks. Its P/E of 19.1× is higher than 56% of its own last 11 years (as of 20 November 2026).

Who owns 3B Blackbio DX?

Promoters own 41.0% of 3B Blackbio DX Ltd, foreign institutions 2.5%, domestic institutions 2.3% and the public 54.3% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026).

Does 3B Blackbio DX have too much debt?

No, 3B Blackbio DX Ltd has little debt: its debt is 0.01× its equity, and its operating profit is 5 times its interest bill. At Sep 2026 borrowings were ₹3.0 Cr against equity of ₹348 Cr.

So the returns on this page come from the business, not borrowed money (as of 20 November 2026).

Where is 3B Blackbio DX in its business cycle?

3B Blackbio DX Ltd's FY26 operating margin was 40.1%, against a 13-year range of 4.5% to 66.1%. The latest quarter was 43.8%, the middle of its own range, neither a peak nor a low.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026).

What could break the 3B Blackbio DX story?

Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026).

Is 3B Blackbio DX a stock worth studying right now?

What the numbers show: 3B Blackbio DX Ltd's earnings have grown faster than its share price. Earnings per share grew +19.4% in a year while the price moved +1.8%. The main open question: the next one or two quarters of results.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 20 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.